Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia
· Delayed Price · Currency is AUD 0.615
+0.055 (9.82%)
Feb 21, 2025, 4:10 PM AEST
ASX:PAR Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | - | - | 0.08 | 0.02 | - | Upgrade
|
| Revenue | - | - | 0.08 | 0.02 | - | Upgrade
|
| Revenue Growth (YoY) | - | - | 285.52% | - | - | Upgrade
|
| Cost of Revenue | 0.01 | 0.02 | 0.14 | 0.1 | - | Upgrade
|
| Gross Profit | -0.01 | -0.02 | -0.06 | -0.08 | - | Upgrade
|
| Selling, General & Admin | 6.77 | 7.39 | 8.85 | 9.59 | 2.94 | Upgrade
|
| Research & Development | 58.33 | 52.68 | 39.01 | 33.52 | 14.02 | Upgrade
|
| Operating Expenses | 65.1 | 60.07 | 47.87 | 43.1 | 16.96 | Upgrade
|
| Operating Income | -65.11 | -60.09 | -47.93 | -43.18 | -16.96 | Upgrade
|
| Interest Expense | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.41 | 1.4 | 0.05 | 0.21 | 1 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.05 | -0.39 | 0.89 | 0.31 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 6.11 | 7.09 | 7.76 | 8.4 | 3.7 | Upgrade
|
| EBT Excluding Unusual Items | -58.65 | -52 | -39.25 | -34.3 | -12.3 | Upgrade
|
| Other Unusual Items | - | 0.09 | - | - | - | Upgrade
|
| Pretax Income | -58.65 | -51.91 | -39.25 | -34.3 | -12.3 | Upgrade
|
| Net Income | -58.65 | -51.91 | -39.25 | -34.3 | -12.3 | Upgrade
|
| Net Income to Common | -58.65 | -51.91 | -39.25 | -34.3 | -12.3 | Upgrade
|
| Shares Outstanding (Basic) | 293 | 250 | 233 | 230 | 201 | Upgrade
|
| Shares Outstanding (Diluted) | 293 | 250 | 233 | 230 | 201 | Upgrade
|
| Shares Change (YoY) | 17.43% | 7.34% | 1.21% | 14.32% | 40.59% | Upgrade
|
| EPS (Basic) | -0.20 | -0.21 | -0.17 | -0.15 | -0.06 | Upgrade
|
| EPS (Diluted) | -0.20 | -0.21 | -0.17 | -0.15 | -0.06 | Upgrade
|
| Free Cash Flow | -65.94 | -45.19 | -32.21 | -34.96 | -10.22 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.18 | -0.14 | -0.15 | -0.05 | Upgrade
|
| Gross Margin | - | - | -81.45% | - | - | Upgrade
|
| Operating Margin | - | - | -60498.78% | -210124.37% | - | Upgrade
|
| Profit Margin | - | - | -49542.54% | -166896.27% | - | Upgrade
|
| Free Cash Flow Margin | - | - | -40650.90% | -170122.95% | - | Upgrade
|
| EBITDA | -64.97 | -59.93 | -47.74 | -43.13 | -16.88 | Upgrade
|
| D&A For EBITDA | 0.15 | 0.15 | 0.19 | 0.05 | 0.08 | Upgrade
|
| EBIT | -65.11 | -60.09 | -47.93 | -43.18 | -16.96 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.